biostudies-literatureWijngaarden JEBoehringer Ingelheim719-729https://www.ebi.ac.uk/biostudies/studies/S-EPMC11732896biostudies-literatureUnknown52(2)<h4>Introduction</h4>The novel positron emission tomography (PET) imaging tracer, [¹⁸F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [¹⁸F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.<h4>Methods</h4>Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input fEuropean journal of nuclear medicine and molecular imagingPharmacokinetic analysis and simplified uptake measures for tumour lesion [&lt;sup&gt;18&lt;/sup&gt;F]F-AraG PET imaging in patients with non-small cell lung cancer.PMC11732896Boehringer IngelheimLevi JWijngaarden JEWindhorst ADOordt CWMHVOprea-Lager DESlebe MDickhoff CThiele ASchuit RCBoellaard RYaqub MBahce IPouw JEEfalsePharmacokinetic analysis and simplified uptake measures for tumour lesion [&lt;sup&gt;18&lt;/sup&gt;F]F-AraG PET imaging in patients with non-small cell lung cancer.<h4>Introduction</h4>The novel positron emission tomography (PET) imaging tracer, [¹⁸F]F-AraG, targets activated T-cells, offering a potential means to improve our understanding of immune-oncological processes. The aim of this study was to determine the optimal pharmacokinetic model to quantify tumour lesion [¹⁸F]F-AraG uptake in patients with non-small cell lung cancer (NSCLC), and to validate simplified measures at different time intervals against the pharmacokinetic uptake parameter.<h4>Methods</h4>Ten patients with early-stage NSCLC and three patients with advanced NSCLC underwent a dynamic PET scan of minimal 60 min. Venous and/or arterial blood sampling was obtained at maximum seven time points. Tumour lesion time activity curves and metabolite-corrected input f2025-01-01T00:00:00Z2025 Jan2026-06-01T20:07:47.366Z2025-04-06T01:16:14.398ZS-EPMC117328963937781010.1007/s00259-024-06931-3